

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/170909 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 1/16 (2006.01)
C07D 487/04 (2006.01) A61P 9/00 (2006.01)
A61K 31/437 (2006.01) A61P 13/12 (2006.01)
A61K 31/501 (2006.01) A61P 25/00 (2006.01)
A61K 31/506 (2006.01) A61P 29/00 (2006.01)
A61K 31/519 (2006.01) A61P 37/06 (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:

PCT/GB2024/050413

(22) International Filing Date:

15 February 2024 (15.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2302205.6 16 February 2023 (16.02.2023) GB

(71) Applicant: **REDX PHARMA LIMITED** [GB/GB]; Block
33 Mereside, Alderley Park, Macclesfield, SK10 4TG (GB).

(72) Inventors: **GUISOT, Nicolas E.S.**; c/o Redx Pharma PLC,
Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG
(GB). **BHAMRA, Inder**; c/o Redx Pharma PLC, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
JONES, Clifford D.; c/o Redx Pharma PLC, Mereside,
Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
RYAN, James; c/o Redx Pharma PLC, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG (GB). **ANDRÁ,**
Michal; c/o Redx Pharma PLC, Mereside, Alderley Park,
Macclesfield, Cheshire SK10 4TG (GB). **VARELA RO-**
DRÍGUEZ, Ana; c/o Redx Pharma PLC, Mereside, Alder-
ley Park, Macclesfield, Cheshire SK10 4TG (GB). **GIG-**
NOUX, Camille; c/o Redx Pharma PLC, Mereside, Alder-
ley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **HGF LIMITED**; 1 City Walk, Leeds, West York-
shire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

WO 2024/170909 A1

(54) Title: DDR1 AND DDR2 INHIBITORS HAVING A DIHYDROBENZIMIDAZOLONE CORE

(57) Abstract: This invention relates to novel compounds and pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as inhibitors of discoidin domain receptor 1 (DDR1) and discoidin domain receptor 2 (DDR2). The compounds are particularly useful in the treatment of cancer and fibrotic diseases.